Ortho-McNeil Pharmaceuticals Overview
- Year Founded
-
1993
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Ortho-McNeil Pharmaceuticals General Information
Description
Developer of medicines designed to use the best internal and external science to transform how diseases are prevented, intercepted, treated and cured. The company's medicines are tested on laboratories and animals before applying it to humans, enabling consumers to get assurance on quality.
Contact Information
Corporate Office
- 1000 U.S. Route 202 South
- Raritan, NJ 08869
- United States
Corporate Office
- 1000 U.S. Route 202 South
- Raritan, NJ 08869
- United States
Ortho-McNeil Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 01-Dec-1996 | Completed | Generating Revenue | |||
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Merger of Equals | 01-Jan-1993 | Completed | Startup |
Ortho-McNeil Pharmaceuticals Comparisons
Industry
Financing
Details
Ortho-McNeil Pharmaceuticals Competitors (10)
One of Ortho-McNeil Pharmaceuticals’s 10 competitors is The Zambon Group, a Private Debt Financed company based in Bresso, Italy.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| The Zambon Group | Private Debt Financed | Bresso, Italy | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Boehringer Ingelheim | Corporation | Ingelheim Am Rhein, Germany | ||||
| Sanofi Pasteur | Corporation | Paris, France | ||||
| CSL Behring | Corporation | King Of Prussia, PA |
Ortho-McNeil Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ortho-McNeil Pharmaceuticals Patents
Ortho-McNeil Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040180867-A1 | Daily administration of 17 beta-estradiol and every other day including norgestimate | Active | 30-Mar-1999 | ||
| US-7078394-B2 | Dominant estrogenic activity phase of three daily doses of an estrogen equivalent to 1 mg per day of 17 beta -estradiol per day and a dominant progestagenic activity phase of a combination of an estrogen as above and a progestogen equivalent to 90 mu g per day of norgestimate. | Inactive | 30-Mar-1999 | ||
| US-6136559-A | Isolated, purified cdna having defined nucleotide sequence; for diagnosis and treatment of central nervous system disorders, anxiety, psychoses, schizophrenia, dyskinesia, parkinson's disease, obesity, tourette's syndrome, and others | Inactive | 07-Oct-1998 | ||
| US-6437100-B1 | Treating nervous system, psychological, respiratory system, brain, sexual, urogenital, and eating disorders; medical diagnosis | Inactive | 07-Oct-1998 | ||
| US-6413743-B1 | Amino acid sequence of protein which has greater inhibition of histamine controlled cyclic amp by thioperamide than by diphenhydramine or ranitidine; nervous system disorders | Inactive | 07-Oct-1998 | C07K14/723 |
Ortho-McNeil Pharmaceuticals Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| TechAcq Ventures | PE/Buyout | Minority |
Ortho-McNeil Pharmaceuticals Investments & Acquisitions (7)
Ortho-McNeil Pharmaceuticals’s most recent deal was a PIPE with Arrowhead Pharmaceuticals for . The deal was made on 04-Oct-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 04-Oct-2018 | PIPE | Biotechnology | ||
| Tesaro | 18-Apr-2016 | PIPE | Pharmaceuticals | ||
| Protectimmun | 28-Sep-2015 | Grant | Drug Discovery | ||
| XO1 | 19-Mar-2015 | Merger/Acquisition | Biotechnology | ||
| Vedanta Biosciences (VE202 microbiome) | 13-Jan-2015 | Corporate Asset Purchase | Buildings and Property |
Ortho-McNeil Pharmaceuticals FAQs
-
When was Ortho-McNeil Pharmaceuticals founded?
Ortho-McNeil Pharmaceuticals was founded in 1993.
-
Where is Ortho-McNeil Pharmaceuticals headquartered?
Ortho-McNeil Pharmaceuticals is headquartered in Raritan, NJ.
-
What industry is Ortho-McNeil Pharmaceuticals in?
Ortho-McNeil Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Ortho-McNeil Pharmaceuticals a private or public company?
Ortho-McNeil Pharmaceuticals is a Private company.
-
What is Ortho-McNeil Pharmaceuticals’s current revenue?
The current revenue for Ortho-McNeil Pharmaceuticals is .
-
Who are Ortho-McNeil Pharmaceuticals’s investors?
TechAcq Ventures has invested in Ortho-McNeil Pharmaceuticals.
-
Who are Ortho-McNeil Pharmaceuticals’s competitors?
The Zambon Group, Genentech, Boehringer Ingelheim, Sanofi Pasteur, and CSL Behring are some of the 10 competitors of Ortho-McNeil Pharmaceuticals.
-
When was Ortho-McNeil Pharmaceuticals acquired?
Ortho-McNeil Pharmaceuticals was acquired on 01-Dec-1996.
-
Who acquired Ortho-McNeil Pharmaceuticals?
Ortho-McNeil Pharmaceuticals was acquired by Johnson&Johnson Innovative Medicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
